B 973B

Key Product Details

Product Description

B 973B is a positive allosteric modulator of α7 nAChRs (EC₅₀ ~0.3 μM); active enantiomer. Increases potency of acetylcholine (EC₅₀ values are 0.007 mM and 0.3 mM in the presence and absence of B 937B, respectively). Potentiates peak acetylcholine-induced currents 6-fold relative to maximal acetylcholine, and slows channel desensitization, resulting in a 6900-fold increase in charge transfer. Decreases paw edema in vivo. Analgesic.

Product Specifications for B 973B

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for B 973B

The following data is based on the product molecular weight 452.50.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.21 mL	11.05 mL	22.10 mL
5 mM	0.44 mL	2.21 mL	4.42 mL
10 mM	0.22 mL	1.10 mL	2.21 mL
50 mM	0.04 mL	0.22 mL	0.44 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Post-Munson B-973, a novel piperazine positive allosteric modulator of the α7 nicotinic acetylcholine receptor. Eur.J.Pharmacol. 2017 PMID: 28132910
• Quadri Macroscopic and microscopic activation of a7 nicotinic acetylcholine receptors by the structurally unrelated allosteric agonist-positive allosteric modulators (ago-PAMs) B-973B and GAT107. Mol.Pharmacol. 2019 PMID: 30348894
• Garai B-973, a novel α7 nAChR Ago-PAM: racemic and asymmetric synthesis, electrophysiological studies, and in vivo evaluation. ACS Med.Chem.Lett. 2018 PMID: 30429960

Product Documents for B 973B